OPKO Health (NASDAQ:OPK) Stock Rating Upgraded by StockNews.com

OPKO Health (NASDAQ:OPK) was upgraded by equities researchers at StockNews.com from a “sell” rating to a “hold” rating in a research note issued on Tuesday.

OPK has been the topic of a number of other reports. HC Wainwright restated a “buy” rating and issued a $3.00 price target on shares of OPKO Health in a report on Thursday, September 26th. Piper Sandler reaffirmed an “overweight” rating and set a $3.00 target price on shares of OPKO Health in a research report on Tuesday, September 17th. Finally, Barrington Research reiterated an “outperform” rating and issued a $2.25 price target on shares of OPKO Health in a report on Friday, November 8th.

OPKO Health Price Performance

OPK opened at $1.48 on Tuesday. The business has a fifty day moving average of $1.54 and a 200 day moving average of $1.50. The stock has a market cap of $1.01 billion, a P/E ratio of -7.79 and a beta of 1.63. The company has a quick ratio of 2.69, a current ratio of 2.97 and a debt-to-equity ratio of 0.30. OPKO Health has a 52-week low of $0.86 and a 52-week high of $1.76.

Insider Transactions at OPKO Health

In related news, CEO Phillip Md Et Al Frost acquired 100,000 shares of the firm’s stock in a transaction that occurred on Thursday, November 14th. The stock was purchased at an average cost of $1.62 per share, for a total transaction of $162,000.00. Following the purchase, the chief executive officer now directly owns 211,612,405 shares of the company’s stock, valued at $342,812,096.10. This trade represents a 0.05 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this link. In the last quarter, insiders acquired 1,304,255 shares of company stock valued at $2,024,605. Company insiders own 47.26% of the company’s stock.

Institutional Trading of OPKO Health

Hedge funds have recently modified their holdings of the company. CIBC Asset Management Inc raised its stake in shares of OPKO Health by 79.1% during the 2nd quarter. CIBC Asset Management Inc now owns 20,322 shares of the biotechnology company’s stock worth $25,000 after acquiring an additional 8,978 shares in the last quarter. FMR LLC grew its holdings in OPKO Health by 103.6% in the third quarter. FMR LLC now owns 21,795 shares of the biotechnology company’s stock worth $32,000 after purchasing an additional 11,089 shares during the last quarter. Algert Global LLC purchased a new stake in shares of OPKO Health during the 2nd quarter valued at $44,000. Orion Portfolio Solutions LLC acquired a new stake in shares of OPKO Health in the 3rd quarter worth $45,000. Finally, Private Advisor Group LLC boosted its position in shares of OPKO Health by 242.7% in the 3rd quarter. Private Advisor Group LLC now owns 35,301 shares of the biotechnology company’s stock worth $53,000 after purchasing an additional 25,000 shares in the last quarter. 64.63% of the stock is owned by hedge funds and other institutional investors.

OPKO Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.